Updated: FDA adcomm splits votes on Genentech and J&J cancer drugs

The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US patient population for a Columvi label expansion. In the afternoon session, the same committee voted ...